Concepedia

Edward S. Kim

ES

Statistics

Publications

124

Citations

15.5K

H-Index

59

Active since

1998

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Levine Cancer Institute

Carolinas Healthcare System

Emory University

Samsung Medical Center

Edward S. Kim is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1998–2024

124

Publications

124

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok et al. · The Lancet · 2008 · 1.2K citations

, , +8

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

, , +17

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim, Roy S. Herbst, Ignacio I. Wistuba et al. · Cancer Discovery · 2011 · 893 citations

, , +17

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 628 citations · Full text

, , +17

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2017 · 583 citations · Full text

, , +15

1–5 of 124